Literature DB >> 12829215

[Value of eosinopenia in inflammatory disorders: an "old" marker revisited].

H Gil1, N Magy, F Mauny, J-L Dupond.   

Abstract

PURPOSE: The value of eosinopenia as a test in favour of an infectious disease was suggested by Schilling since 1929. We tried to verify this hypothesis with a prospective and multicentric study. PATIENTS AND METHODS: One thousand and thirty-eight patients were included (82 females and 56 males, means age: 71.8 years). Diagnoses were: 83 infectious diseases, 38 systemic diseases, 10 neoplasia and 7 miscellaneous.
RESULTS: The mean value of eosinophils was 72/mm3 in bacterial infectious diseases and 214/mm3 in non infectious diseases (p < 0.01). When leukocytes were higher than 10,000/mm3 and eosinophils counts less than 40/mm3, predictive value for an infectious bacterial disease was 100% as well as specificity. Under same conditions, when protein C reactive was higher than 100mg x l(-1), the predictive value was 85% and the specificity was 57%.
CONCLUSION: Our study shows that an inflammatory syndrome associated with hyperleucocytosis above 10,000/mm3 and eosinophils counts under 40/mm3 seems strongly related to bacterial infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829215     DOI: 10.1016/s0248-8663(03)00138-3

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  24 in total

1.  Hematological features in adolescents with periodontitis.

Authors:  Rodrigo López; Bruno G Loos; Vibeke Baelum
Journal:  Clin Oral Investig       Date:  2011-10-19       Impact factor: 3.573

2.  Usefulness of blood cultures in the management of febrile patients in long-term care facilities.

Authors:  R Raz; Y Ben-Israel; D Gronich; E Granot; R Colodner; I Visotzky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-11       Impact factor: 3.267

3.  Eosinopenia, an early marker of increased mortality in critically ill medical patients.

Authors:  Khalid Abidi; Jihane Belayachi; Youssef Derras; Mina El Khayari; Tarek Dendane; Naoufel Madani; Ibtissam Khoudri; Amine Ali Zeggwagh; Redouane Abouqal
Journal:  Intensive Care Med       Date:  2011-03-03       Impact factor: 17.440

Review 4.  Eosinophils in mucosal immune responses.

Authors:  J Travers; M E Rothenberg
Journal:  Mucosal Immunol       Date:  2015-03-25       Impact factor: 7.313

Review 5.  Year in review 2008: Critical Care--sepsis.

Authors:  Steven M Opal; Steven P LaRosa
Journal:  Crit Care       Date:  2009-10-21       Impact factor: 9.097

6.  Prognostic usefulness of eosinopenia in the pediatric intensive care unit.

Authors:  Yoon Hee Kim; Hyun Bin Park; Min Jung Kim; Hwan Soo Kim; Hee Seon Lee; Yoon Ki Han; Kyung Won Kim; Myung Hyun Sohn; Kyu-Earn Kim
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

7.  Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units.

Authors:  Khalid Abidi; Ibtissam Khoudri; Jihane Belayachi; Naoufel Madani; Aicha Zekraoui; Amine Ali Zeggwagh; Redouane Abouqal
Journal:  Crit Care       Date:  2008-04-24       Impact factor: 9.097

8.  Is eosinopenia a reliable marker of sepsis?

Authors:  Alex Smithson; Rafael Perelló; Josep-Maria Nicolas
Journal:  Crit Care       Date:  2009-06-01       Impact factor: 9.097

9.  Neutrophil-Related Ratios Predict the 90-Day Outcome in Acute Ischemic Stroke Patients After Intravenous Thrombolysis.

Authors:  Beibei Gao; Wenjing Pan; Xueting Hu; Honghao Huang; Junli Ren; Chenguang Yang; Xinbo Zhou; Tian Zeng; Jingyu Hu; Shengqi Li; Yufan Gao; Shunkai Zhang; Guangyong Chen
Journal:  Front Physiol       Date:  2021-07-02       Impact factor: 4.566

10.  Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia: a retrospective cohort study.

Authors:  Roser Terradas; Santiago Grau; Jordi Blanch; Marta Riu; Pere Saballs; Xavier Castells; Juan Pablo Horcajada; Hernando Knobel
Journal:  PLoS One       Date:  2012-08-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.